1 From The Cardiovascular Research Laboratory, Georgetown University Hospital, the Department of Medicine, Georgetown University School of Medicine, and the Veterans Administration Hospital, Washington, D. C.
The new ganglionic blocking agent, pentapyrrolidinium or M&B 2050, appears to have several distinct advantages over hexamethonium in the treatment of severe hypertension. These advantages include longer duration of action, greater potency, less tolerance, less interference with intestinal motility, and, most important, a more uniform response from day to day on oral administration. However, critical adjustment of dosage is necessary and side effects are not infrequent, the most disturbing being postural faintness and impotence.
© 1954 American Heart Association, Inc.
A Clinical Appraisal of Pentapyrrolidinium (M&B 2050) in Hypertensive Patients
This article has been cited by other articles:
![]() |
M. A. Lindauer and J. H. Hafken Schiel Hexamethonium Chloride With Reserpine in the Treatment of Severe Essential Hypertension Angiology, February 1, 1958; 9(1): 19 - 23. [PDF] |
||||
![]() |
E. D. FREIS and I. M. WILSON Mecamylamine, a New, Orally Effective, Experimental and Clinical Evaluation Arch Intern Med, May 1, 1956; 97(5): 551 - 561. [Abstract] [PDF] |
||||
![]() |
W. M. KIRKENDALL and J. W. CULBERTSON MANAGEMENT OF SYSTEMIC ARTERIAL HYPERTENSION Arch Intern Med, April 1, 1955; 95(4): 601 - 613. [Abstract] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1954 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |